Fennec Pharmaceuticals Inc. (FENC): Price and Financial Metrics
GET POWR RATINGS... FREE!
FENC Stock Price Chart Interactive Chart >
FENC Price/Volume Stats
| Current price | $8.55 | 52-week high | $10.85 |
| Prev. close | $8.32 | 52-week low | $5.00 |
| Day low | $7.98 | Volume | 218,300 |
| Day high | $8.71 | Avg. volume | 95,562 |
| 50-day MA | $9.11 | Dividend yield | N/A |
| 200-day MA | $8.15 | Market Cap | 225.77M |
Fennec Pharmaceuticals Inc. (FENC) Company Bio
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, a water soluble thiol compound that acts as a chemical reducing agent, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was founded in 1996 and is based in Research Triangle Park, North Carolina.
Latest FENC News From Around the Web
Below are the latest news stories about FENNEC PHARMACEUTICALS INC that investors may wish to consider to help them evaluate FENC as an investment opportunity.
7 Biotech Stocks Sitting in the Sweet SpotBiotech stocks have the potential for massive profits if their companies are successful in developing drugs that are safe and marketable. |
Why Earnings Season Could Be Great for Adherex Technologies (FENC)Adherex Technologies (FENC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season. |
Fennec Pharmaceuticals Announces PEDMARK® (sodium thiosulfate injection) Receives Orphan Drug Exclusivity from U.S. FDA~ PEDMARK® is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-Metastatic Solid Tumors ~ ~ Orphan Drug Exclusivity Provides Seven Years of Market Exclusivity for PEDMARK® from its FDA Approval on September 20, 2022 Until September 20, 2029 ~ ~ Additionally, the Company Has Three FDA Orange Book Listings Providing U.S. Patent Protection for PEDMARK® Until 2039 ~ RESEARCH TRIANGLE PARK, N.C., Jan |
Fennec Pharmaceuticals Announces Updated NCCN Clinical Practice Guidelines Recommend PEDMARK® (sodium thiosulfate injection) to Reduce the Risk of Cisplatin-Induced Hearing Loss in Pediatric Patients~ PEDMARK is the First and Only FDA-Approved Therapy Indicated to Reduce the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients with Localized, Non-metastatic Solid Tumors ~ ~ The 5-year Survival Rate for Childhood Cancers Due to Major Treatment Advances is Now 85 Percent or Higher,1 Underscoring Need to Mitigate the Profound Impact Hearing Loss Can Have on a Child’s Learning and Development ~ RESEARCH TRIANGLE PARK, N.C., Jan. 25, 2023 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals |
RTP drugmaker Fennec sues Cipla over generics effortCipla Ltd. wants to make generic versions of Research Triangle Park drugmaker Fennec's lone product. |
FENC Price Returns
| 1-mo | -6.46% |
| 3-mo | -10.94% |
| 6-mo | 5.56% |
| 1-year | 52.68% |
| 3-year | 187.88% |
| 5-year | 41.38% |
| YTD | -10.94% |
| 2022 | 118.18% |
| 2021 | 18.12% |
| 2020 | 14.79% |
| 2019 | 1.72% |
| 2018 | -36.33% |
Loading social stream, please wait...